The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 01, 2014

Filed:

Feb. 03, 2007
Applicants:

Thomas Weimer, Gladenbach, DE;

Stefan Schulte, Marburg, DE;

Ulrich Kronthaler, Marburg, DE;

Wiegand Lang, Cölbe, DE;

Uwe Liebing, Cölbe, DE;

Wilfried Wormsbächer, Kirchhain, DE;

Inventors:

Thomas Weimer, Gladenbach, DE;

Stefan Schulte, Marburg, DE;

Ulrich Kronthaler, Marburg, DE;

Wiegand Lang, Cölbe, DE;

Uwe Liebing, Cölbe, DE;

Wilfried Wormsbächer, Kirchhain, DE;

Assignee:

CSL Behring GmbH, Marburg, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/35 (2006.01); A61K 38/38 (2006.01); C07K 14/745 (2006.01); C07K 14/76 (2006.01); C07K 14/765 (2006.01); C12N 9/64 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C12N 9/6437 (2013.01); C07K 14/76 (2013.01); C12Y 304/21021 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01);
Abstract

The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.


Find Patent Forward Citations

Loading…